Alembic receives FDA OK for generic Arranon
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and lymphoma in certain patients.
Alembic has received the Food and Drug Administration’s permission for Nelarabine Injection, 250 mg/50 ml (5 mg/ml) (single-dose vial).
The medication is the generic of Sandoz’s Arranon Injection.
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
[Read more: Alembic intros generic Perforomist]
Nelarabine Injection, 250 mg/50 ml has a market value of roughly $23 million for the 12 months ending March 2024, per IQVIA.